The latest update is out from Standard BioTools ( (LAB) ).
Standard BioTools Inc. has updated its investor presentation, outlining its vision and growth strategy, including a revenue forecast for 2024 and a plan to break even on adjusted EBITDA by 2026. The presentation emphasizes the company’s focus on proteomics and multi-omics platforms, strategic mergers and acquisitions, and partnerships to enhance its portfolio and drive profitability. The company stresses that its forward-looking statements are subject to risks and uncertainties and that non-GAAP financial measures are used alongside GAAP measures to better represent its operational performance.
See more insights into LAB stock on TipRanks’ Stock Analysis page.
